Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Phase 1/2 Withdrawn
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
Phase 1/2 Withdrawn
PICH
Phase 1/2 Withdrawn
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1/2 Withdrawn
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase 1/2 Withdrawn
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
Phase 1/2 Withdrawn
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Phase 1/2 Withdrawn
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
Phase 1/2 Withdrawn
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
Phase 1/2 Withdrawn
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
Phase 1/2 Withdrawn
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 1/2 Withdrawn
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Withdrawn